VMY-1-103
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
708.27
Molecular Formula
C34H42ClN9O4S
Notes
Research use only, not for human use.
Receptor
CDK
CAS Number
1209002-43-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6285151-01 0.2 mL
CENTG1, CT (AGAP2, CENTG1, KIAA0167, Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2, Centaurin-gamma-1, GTP-binding and GTPase-activating protein 2, Phosphatidylinositol 3-kinase enhancer) (APC)
Ask
View Details 
MBS6285151-02 5x 0.2 mL
CENTG1, CT (AGAP2, CENTG1, KIAA0167, Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2, Centaurin-gamma-1, GTP-binding and GTPase-activating protein 2, Phosphatidylinositol 3-kinase enhancer) (APC)
Ask
View Details 
MBS7008565-01 0.02 mg
Recombinant Acinetobacter baumannii ATP synthase subunit a (atpB)
Ask
View Details MBS7008565-02 0.1 mg
Recombinant Acinetobacter baumannii ATP synthase subunit a (atpB)
Ask
View Details MBS7008565-03 5x 0.1 mg
Recombinant Acinetobacter baumannii ATP synthase subunit a (atpB)
Ask
View Details